Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine

Xavier Cubiró; Sergi Planas-Ciudad; Mª Pilar Garcia-Muret; Lluís Puig

doi:10.1001/jamadermatol.2017.4120

Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine

JAMA Dermatol. 2018 Jan 1;154(1):99-100. doi: 10.1001/jamadermatol.2017.4120.

Authors

Xavier Cubiró¹, Sergi Planas-Ciudad¹, Mª Pilar Garcia-Muret¹, Lluís Puig¹

Affiliation

¹ Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Abstract

This study evaluated the efficacy and tolerability of topical timolol, 0.5%, gel as a treatment of paronychia and pseudopyogenic granuloma induced by antineoplastic agents.

MeSH terms

Administration, Topical
Aged
Angiolymphoid Hyperplasia with Eosinophilia / chemically induced*
Angiolymphoid Hyperplasia with Eosinophilia / drug therapy*
Antimetabolites, Antineoplastic / adverse effects*
Antimetabolites, Antineoplastic / therapeutic use
Capecitabine / adverse effects*
Capecitabine / therapeutic use
Cohort Studies
Female
Humans
Male
Middle Aged
Neoplasms / drug therapy
Neoplasms / pathology
Paronychia / chemically induced*
Paronychia / drug therapy*
Prognosis
Retrospective Studies
Timolol / administration & dosage*
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Capecitabine
Timolol